$KPTI
Karyopharm Therapeutics Inc.

2018 Q4 Form 10-Q Financial Statement

#000119312518322696 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $206.0K $239.0K $0.00
YoY Change -86.57% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.77M $12.97M $5.820M
YoY Change 205.2% 122.85% -1.36%
% of Gross Profit
Research & Development $38.89M $36.43M $25.24M
YoY Change 11.66% 44.34% 26.86%
% of Gross Profit
Depreciation & Amortization $200.0K $190.0K $180.0K
YoY Change 17.65% 5.56% 0.0%
% of Gross Profit
Operating Expenses $57.66M $49.39M $31.06M
YoY Change 40.68% 59.05% 20.41%
Operating Profit -$57.46M -$49.15M -$31.06M
YoY Change 45.63% 58.28% 20.64%
Interest Expense -$730.0K $1.100M $450.0K
YoY Change -269.77% 144.44% 45.16%
% of Operating Profit
Other Income/Expense, Net -$755.0K $1.085M $428.0K
YoY Change -279.33% 153.5% 35.02%
Pretax Income -$58.19M -$48.07M -$30.63M
YoY Change 49.09% 56.95% 20.46%
Income Tax $20.00K $14.00K $13.00K
% Of Pretax Income
Net Earnings -$58.21M -$48.08M -$30.64M
YoY Change 49.1% 56.93% 20.51%
Net Earnings / Revenue -28257.28% -20118.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$957.4K -$793.5K -$650.0K
COMMON SHARES
Basic Shares Outstanding 60.71M shares 60.56M shares 47.14M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $328.2M $206.8M $119.4M
YoY Change 124.07% 73.17% -5.84%
Cash & Equivalents $118.0M $101.6M $54.45M
Short-Term Investments $210.2M $105.2M $65.00M
Other Short-Term Assets $6.400M $4.800M $2.300M
YoY Change 220.0% 108.7% -32.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $334.6M $211.6M $121.7M
YoY Change 125.44% 73.86% -6.58%
LONG-TERM ASSETS
Property, Plant & Equipment $3.863M $2.914M $2.304M
YoY Change 76.8% 26.48% -22.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M $4.800M $39.50M
YoY Change -93.2% -87.85% -20.36%
Other Assets $700.0K $700.0K $300.0K
YoY Change 133.33% 133.33% 0.33%
Total Long-Term Assets $6.580M $8.430M $42.09M
YoY Change -79.35% -79.97% -21.14%
TOTAL ASSETS
Total Short-Term Assets $334.6M $211.6M $121.7M
Total Long-Term Assets $6.580M $8.430M $42.09M
Total Assets $341.2M $220.0M $163.8M
YoY Change 89.24% 34.33% -10.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.332M $2.238M $1.890M
YoY Change -23.53% 18.41% -13.82%
Accrued Expenses $32.49M $29.16M $17.72M
YoY Change 51.52% 64.58% 43.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.90M $41.57M $21.16M
YoY Change -5.18% 96.49% 41.49%
LONG-TERM LIABILITIES
Long-Term Debt $102.7M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.500M $7.300M $1.400M
YoY Change 507.14% 421.43% -17.65%
Total Long-Term Liabilities $111.2M $7.300M $1.400M
YoY Change 7842.86% 421.43% -17.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.90M $41.57M $21.16M
Total Long-Term Liabilities $111.2M $7.300M $1.400M
Total Liabilities $158.0M $48.91M $22.60M
YoY Change 210.88% 116.47% 35.38%
SHAREHOLDERS EQUITY
Retained Earnings -$673.7M -$615.5M -$456.3M
YoY Change 36.02% 34.9% 34.53%
Common Stock $857.2M $786.8M $597.6M
YoY Change 37.14% 31.66% 18.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $183.2M $171.1M $141.2M
YoY Change
Total Liabilities & Shareholders Equity $341.2M $220.0M $163.8M
YoY Change 89.24% 34.33% -10.81%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$58.21M -$48.08M -$30.64M
YoY Change 49.1% 56.93% 20.51%
Depreciation, Depletion And Amortization $200.0K $190.0K $180.0K
YoY Change 17.65% 5.56% 0.0%
Cash From Operating Activities -$48.17M -$38.67M -$21.75M
YoY Change 769.49% 77.79% 6.98%
INVESTING ACTIVITIES
Capital Expenditures -$1.090M -$490.0K -$10.00K
YoY Change 2080.0% 4800.0%
Acquisitions
YoY Change
Other Investing Activities -$102.0M $21.06M $20.61M
YoY Change 3479.65% 2.18% -514.69%
Cash From Investing Activities -$103.1M $20.57M $20.60M
YoY Change 3455.52% -0.15% -513.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 167.8M 770.0K 160.0K
YoY Change 631.07% 381.25% -99.49%
NET CHANGE
Cash From Operating Activities -48.17M -38.67M -21.75M
Cash From Investing Activities -103.1M 20.57M 20.60M
Cash From Financing Activities 167.8M 770.0K 160.0K
Net Change In Cash 16.50M -17.33M -990.0K
YoY Change 13.71% 1650.51% -116.05%
FREE CASH FLOW
Cash From Operating Activities -$48.17M -$38.67M -$21.75M
Capital Expenditures -$1.090M -$490.0K -$10.00K
Free Cash Flow -$47.08M -$38.18M -$21.74M
YoY Change 757.56% 75.62% 6.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60707876 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54450000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54939000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
289000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29155000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
211562000
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
180850000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3443000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3099000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
786763000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2238000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-153000
CY2018Q3 us-gaap Assets
Assets
219992000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
154000
CY2018Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
81222000
CY2018Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
109974000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4804000
CY2018Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
41 Securities
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
110122000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
105170000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101600000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102312000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60664857 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60664857 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
256000
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2815000
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9362000
CY2018Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4532000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7349000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
41567000
CY2018Q3 us-gaap Liabilities
Liabilities
48914000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
219992000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
556000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2914000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4792000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
712000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6013000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-615538000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
171078000
CY2018Q3 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
18118000
CY2018Q3 kpti Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
211574000
CY2018Q3 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50142000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21445000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
148423000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
148673000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
972000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2558000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5665000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2017Q4 us-gaap Assets
Assets
180294000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
96623000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
106868000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29396000
CY2017Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
54 Securities
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
107121000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77472000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68997000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69487000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49533150 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49533150 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
303000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1363000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21921000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3982000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
463000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2185000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1754000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49467000
CY2017Q4 us-gaap Liabilities
Liabilities
50830000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180294000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4743000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495341000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
129464000
CY2017Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16198000
CY2017Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-903000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4797000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89760000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
539000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18717000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89890000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2867000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6423000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1050000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
207000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1266000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1196000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20009000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52786000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68179000
us-gaap Net Income Loss
NetIncomeLoss
-89944000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
134000
us-gaap Operating Expenses
OperatingExpenses
91157000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91086000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
74017000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
894000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94033000
us-gaap Profit Loss
ProfitLoss
-89944000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72440000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71000
us-gaap Share Based Compensation
ShareBasedCompensation
15906000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44974945 shares
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
52323000
dei Amendment Flag
AmendmentFlag
false
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-280000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32825000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-120133000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
541000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.17
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9000
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
dei Entity Small Business
EntitySmallBusiness
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30076000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-120188000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3425000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8139000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3039000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8027000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-1405000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2260000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2240000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4554000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
148333000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110945000
us-gaap Net Income Loss
NetIncomeLoss
-120197000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
us-gaap Operating Expenses
OperatingExpenses
152558000
us-gaap Operating Income Loss
OperatingIncomeLoss
-122428000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
97662000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1270000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2627000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94378000
us-gaap Profit Loss
ProfitLoss
-120197000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122482000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30130000
us-gaap Share Based Compensation
ShareBasedCompensation
13378000
dei Trading Symbol
TradingSymbol
KPTI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55465261 shares
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
145706000
CY2017 kpti Tax Cuts And Jobs Act Of2017 Change In Tax Rate Reduction In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets
42763000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30565000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5818000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30627000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
454000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
428000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-30640000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
50000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
31055000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31055000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
296000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25237000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47141146 shares
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47976000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12966000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48069000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1098000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1085000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-48083000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
49393000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-49154000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
895000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36427000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
239000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60586511 shares

Files In Submission

Name View Source Status
0001193125-18-322696-index-headers.html Edgar Link pending
0001193125-18-322696-index.html Edgar Link pending
0001193125-18-322696.txt Edgar Link pending
0001193125-18-322696-xbrl.zip Edgar Link pending
d636603d10q.htm Edgar Link pending
d636603dex311.htm Edgar Link pending
d636603dex312.htm Edgar Link pending
d636603dex321.htm Edgar Link pending
d636603dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20180930.xml Edgar Link completed
kpti-20180930.xsd Edgar Link pending
kpti-20180930_cal.xml Edgar Link unprocessable
kpti-20180930_def.xml Edgar Link unprocessable
kpti-20180930_lab.xml Edgar Link unprocessable
kpti-20180930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending